revenue we are seeing in 2021 and we'll |
5.76 |
Jump to 25.519 |
|
|
probably see in 282 will probably not be |
4.72 |
Jump to 28.32 |
|
|
um the vaccines are running between five |
4.801 |
Jump to 46.879 |
|
|
and seven billion dollars therapies like |
4.08 |
Jump to 49.28 |
MONEY
seven billion dollars
|
|
tammy flu before the one generics we're |
3.68 |
Jump to 51.68 |
|
|
just under five billion so if you take |
3.679 |
Jump to 53.36 |
MONEY
just under five billion
|
|
two is probably where both investors are |
4.721 |
Jump to 57.039 |
|
|
if if we look at 2022 that number will |
4.24 |
Jump to 59.6 |
|
|
probably be exceeded nine fold we |
4.32 |
Jump to 61.76 |
|
|
currently project about 86 billion |
4.88 |
Jump to 63.84 |
|
|
vaccine revenue in 2022 and there will |
4.96 |
Jump to 68.72 |
|
|
in 22 and 2023 before they're able to |
4.799 |
Jump to 106.96 |
|
|
revenue in 24 and 25 typically when |
3.521 |
Jump to 111.759 |
|
|
2022 and very much dependent on on the |
4.881 |
Jump to 131.599 |
|
|
flu is the first program coming out they |
3.679 |
Jump to 175.84 |
|
|
three to four times the cash flow than |
3.92 |
Jump to 216.08 |
|
|
one name that had gotten some play |
3.28 |
Jump to 246.239 |
|
|
strong view on that one way or the other |
4.241 |
Jump to 249.519 |
|
|